Identification of developmental disorders including autism spectrum disorder using salivary miRNAs in children from Bosnia and Herzegovina

Emir Sehovic1☯, Lemana Spahic1☯, Lejla Smajlovic-Skenderagic1ID, Nirvana Pistoljevic2☯, Eldin Dzanko2☯, Aida Hajdarpasic3* ID

1 Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina, 2 Education for All (EDUS), Sarajevo, Bosnia and Herzegovina, 3 Department of Medical Biology, Sarajevo Medical School, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

☯ These authors contributed equally to this work.
* aida.saracevic@ssst.edu.ba

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by major social, communication and behavioural challenges. The cause of ASD is still unclear and it is assumed that environmental, genetic and epigenetic factors influence the risk of ASD occurrence. MicroRNAs (miRNAs) are short 21–25 nucleotide long RNA molecules which post-transcriptionally regulate gene expression. MiRNAs play an important role in central nervous system development; therefore, dysregulation of miRNAs is connected to changes in behaviour and cognition observed in many disorders including ASD. Based on previously published work, on diagnosing ASD using miRNAs, we hypothesized that miRNAs can be used as biomarkers in children with suspected developmental disorders (DD) including ASD within Bosnian-Herzegovinian (B&H) population. 14 selected miRNAs were tested on saliva of children with suspected developmental disorders including ASD. The method of choice was qRT-PCR as a relatively cheap method available in most diagnostic laboratories in low to mid-income countries (LMIC). Out of 14 analysed miRNAs, 6 were differentially expressed between typically developing children and children with some type of developmental disorder including autism spectrum disorder. Using the most optimal logistic regression, we were able to distinguish between ASD and typically developing (TD) children. We have found 5 miRNAs as potential biomarkers. From those, 3 were differentially expressed within the ASD cohort. All 5 miRNAs had shown good chi-square statistics within the logistic regression performed on all 14 analysed miRNAs. The accuracy of 5-miRNAs model training set was 90.2%, while the validation set had a 90% accuracy. This study has shown that miRNAs may be considered as biomarkers for ASD detection and may be used to identify children with ASD along with standard developmental screening tests. By combining these methods we may be able to reach a reliable and accessible diagnostic model for children with ASD in LMIC such as B&H.
Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by major social, communication and behavioural challenges. More specifically, individuals with ASD emit repetitive and restricted behavioural patterns as well as atypical social tendencies, which greatly impacts their daily functioning abilities [1].

The cause of ASD is still unclear and it is assumed that both the environmental and genetic factors together influence the risk of ASD occurrence. ASD as a part of a genetic syndrome is identified in about 10% of all ASD cases and such cases are usually associated with malformations and/or dysmorphic characteristics [2–4]. The genetic contribution to ASD is undoubtedly significant as the concordance rates for monozygotic twins is 58% for male and 60% for female, while for di-zygotic twins it is 21% for male pairs and 27% for female pairs [5]. The concordance rates also show that other factors influence the occurrence of ASD such as epigenetic regulation and environment. Epigenetic gene regulation is an essential mechanism for normal brain development [6] and anomalies in the molecules responsible for this mechanism are known to cause various neurodevelopmental disorders including autism [7–12]. Moreover, prenatal exposure to some of the substances which have been shown to increase the risk of ASD are, among others, thalidomide, misoprostol, valproic acid and chlorpyrifos [13]. Today we know that the effects of prenatal exposure to alcohol, pollution, infections and inflammations, as well as assisted deliveries, have a negative impact on later health and development of a child [14, 15].

The prevalence of ASD, all over the world, has had an increasing trend [16, 17]. The latest report on prevalence in the USA shows 1 in 59 children with ASD [18]. The worldwide prevalence of ASD is estimated to be 1–2% of the population, however, prevalence varies from country to country, mainly depending on how advanced the diagnostic system is and the availability of screening and diagnostic tools [18–22]. In order to detect and diagnose ASD, the American Academy of Paediatrics and the US Preventative Service Task Force suggest the usage of valid and reliable screening and diagnostic tools [23, 24]. Unfortunately, most of these tools are not translated, validated or financially accessible for most low and middle income countries (LMIC) where it has been estimated that 250 million children younger than 5 years are at risk of not achieving full developmental potential [1,25]. Early intervention shows significant outcomes for children with ASD which mostly depends on the early detection and diagnosis of the disorder [26]. Trends of late diagnosis have to be replaced by early diagnosis due to the short window of human brain development, because of which the best results of early intervention are achieved by the age of 5 [27,28].

Bosnia and Herzegovina (B&H) is classified as a mid-income country where parents of children with developmental disorders often encounter difficulties in getting an early diagnosis for their child. Diagnosis in B&H is usually made by a process of exclusion (usually by completing various unnecessary medical tests such as MRI, EEG etc.) and based, in most cases, on clinical evaluation. Experts from various countries point out the need for all countries to develop population-based detection, screening and evidence-based intervention for children in order to increase a chance for social inclusion of all [29]. Recently, a cheap and efficient model for diagnosing ASD emerged in the field of genetics where microRNA analysis showed promising results in distinguishing children with ASD from their typically and atypically developing peers [30]. This combined with validated screening tools could offer an affordable solution for LMIC where access to expensive diagnostic tools hinders the process of diagnosis and therefore intervention itself. Genetic analyses can be performed on samples of various origins, but for the sake of diagnosis, these sources are mostly blood, saliva or buccal swabs. Chosen source for this particular application would be saliva due to the specificity of the target
population. ASD individuals are restless and taking their blood sample or buccal swab is highly demanding even for experienced individuals. On the other hand, saliva can be collected by simple means of saliva collection which is easy to accomplish even with extreme cases of ASD and DD [31–34].

MicroRNAs (miRNAs) are a group of relatively small (around 21 nucleotides) noncoding transcripts that can modify cellular messenger RNAs (mRNAs) and protein levels by interacting with specific mRNAs. The interaction of miRNAs with mRNAs usually occurs at the 3′ untranslated region (UTR) which results in mRNA degradation or repression of translation [35, 36] through partial sequence complementation [37]. It is thought that around 10–30% of all human genes could be miRNA targets [38, 39].

MiRNAs have an important role in central nervous system development and function [40, 41]. Therefore, it is not surprising that the dysregulation of miRNAs is connected to changes in behaviour and cognition observed in many neuropsychiatric disorders [42]. More specifically, miRNAs have important functions in neurogenesis, synaptogenesis and neuronal migration [43]. Usually the main function of miRNAs in these processes affect the spatial localization or compartmentalization of protein translation in different neuronal subregions, such as axons, dendrites, and synapses [44,45]. MiRNAs have been found to be dysregulated in children with ASD in various analysed biomaterials such as post-mortem cerebellar cortex [46], several post-mortem’s Brodmann’s areas [47,48], serum [49], peripheral blood [50,51], whole blood [52], saliva [53], olfactory mucosal stem cells [54], lymphoblast cell lines [55–57].

Successful models for diagnosing ASD utilizing various RNA molecules (miRNA, piRNA, snoRNA etc) obtained from the saliva have been created. The study whose model focused entirely on miRNAs obtained an accuracy higher than 95% [53], while the study which generated a model on various types of RNA molecules obtained a positive predictive value of 91% [58].

In order to explore affordable and quick screening models and detection of developmental disorders including ASD in B&H, we have performed a pilot study on molecular biomarkers as potential detection of atypical development. The aim of this study was to evaluate expression levels of 14 selected miRNAs from saliva of children with suspected developmental disorder and to test their ability to detect developmental disorders (DD) including ASD. The proposed panel was previously tested by Hicks et al., 2016 [53] using Next Generation Sequencing, while our method of choice was qRT-PCR, as a relatively cheap method found in most diagnostics labs in low to mid-income countries such as B&H.

**Materials and methods**

**Participants and assessment**

This study was approved by the EDUS Institutional Review Board for the Protection of Human Subjects (IRB) for all project activities. All participants were recruited through the Non-governmental organization EDUS-Education for All from Sarajevo, the capital of B&H. Informed written parental consent was obtained for a total of 81 participants out of 126 that were enrolled in the EDUS preschool program during the school year 2018/2019. The EDUS preschool program is based on the CABAS® system (Comprehensive Application of Behavior Analysis), an evidence-based approach to assessment and treatment of Developmental Disorders and Autism Spectrum Disorder [59–63]. Children from all over B&H are enrolled in the program receiving services in developmental screening, assessment and/or treatment. One participant was excluded from the study because of the inability to collect saliva resulting in the final sample size of 80 participants consisted of children with detected developmental delays/disorders (DD) (n = 55) and typically developing (TD) pre-school children with no
previously detected developmental problems were classified as the control group (n = 25) (Table 1). The control sample was recruited from several public kindergartens for typically developing children. All data in this study were collected during the period from March to May 2018.

In order to classify participants into DD and TD groups all 80 children went through a developmental screening with the EDUS Developmental Behavioural Scales (EDUS-DBS) [64]. EDUS-DBS covers all five developmental areas: speech and communication, motor development (gross and fine), cognitive development, social-emotional development, and self-help/adaptive skills. The EDUS-DBS screening outcome indicates, for each developmental area separately, whether the child is developing typically or atypically for their chronological age. Children who showed a developmental delay in at least one area mentioned above were selected into the group of children with DD, and children that did not show developmental delays were selected into the group of TD children. The second step was to screen the group of children detected with DD for Autism symptoms with the Childhood Autism Rating Scale, Second edition (CARS-II) [65]. The final raw score of CARS-II classifies each child into one of the three different autism symptoms severity groups: Minimal-to-No Symptoms of ASD, Mild-to-Moderate Symptoms of ASD, and Severe Symptoms of ASD. The third step consisted of clinical observations conducted by an experienced child psychiatrist in the field of ASD. By taking into account the direct observation of the child and information collected from parents about their child’s developmental history, the child psychiatrist concluded two possible outcomes: ASD or DD different from ASD. The child psychiatrist had no access to the CARS-II scores of the DD sample when making conclusions.

After considering the outcomes of the CARS-II and clinical observations of the child psychiatrist, the group of children with DD was divided into two groups: children identified with ASD (n = 39) and children with other DD different from ASD (n = 16). Children identified with ASD showed CARS-II scores that fall into the Mild-to-Moderate and Severe ASD Symptoms category, and children identified with other DD (different from ASD) showed scores that fall into the Minimal-to-No Symptoms of ASD CARS-II category (Table 2). Clinical observations were conducted for 26 children (47.3%) and showed 100% concordance between Child Psychiatrists observations and CARS-II results with the CARS-II classifications (i.e. CARS-II scores indicated Mild-To-Moderate or Severe Symptoms of ASD and clinical opinion concluded ASD, CARS-II scores indicated Minimal-to-No Symptoms of ASD and Clinical opinion concluded that it is another DD different from ASD) (Table 2). Children for clinical observations from a Child Psychiatrist were selected randomly out of the whole DD sample (n = 55). No predetermined criteria for selection of participants was used.

### Molecular analysis

A total of 80 saliva samples were collected in a non-fasting state after rinsing with tap water with at least 30 minutes timespan from the last meal. Approximately 2 mLs of saliva were obtained, per manufacturer’s instructions, using Samplifybio saliva collection kit (Samplifybio, Beverly, MA) and stored at room temperature until processing.

| Characteristics | n (%) | Mean Age expressed in months |
|-----------------|-------|-----------------------------|
| Male            | 11 (44.0%) | 74.9 (SD = 14.4, Min = 54, Max = 95) |
| Female          | 14 (56.0%)  | 64.8 (SD = 12.5, Min = 42, Max = 79) |
| Total           | 25 (100.0%) | 69.3 (SD = 14, Min = 42, Max = 95) |

https://doi.org/10.1371/journal.pone.0232351.t001
For the purpose of analysing 14 miRNAs of interest (miR-628-5p, miR-127-3p, miR-27a-3p, miR-335-3p, miR-2467-5p, miR-30e-5p, miR-28-5p, miR-191-5p, miR-23-3p, miR-3529-5p, miR-218-5p, miR-7-5p, miR-32-5p and miR-140-3p), total RNA was isolated from saliva samples using the mirVANA isolation kit (Invitrogen™), according to the manufacturer’s instructions. The purity of isolated RNA was determined by OD260/280 using a Nanodrop (Thermo Scientific, Worcester, MA).

The miRNAs of interest were reversely transcribed using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems™ Foster City, CA) and specific miRNA reverse transcription (RT) primers, on GS1 Thermal Cycler System (G-Strom) and SimpliAmp Thermal Cycler (Applied Biosystems™ Foster City, CA) according to the manufacturer’s instructions. The purity of isolated RNA was determined by OD260/280 using a Nanodrop (Thermo Scientific, Worcester, MA).

After reverse transcription, due to smaller amounts of RNA within the samples, pre-amplification was performed. For pre-amplification, a custom primer pool was prepared with 14 miRNAs of interest. The total volume of the primer pool contained 70 μL of TaqMan MicroRNA Assay + 430 ddH2O for a total of 500 μL. In the mastermix for the pre-amplification reaction, for each sample, we used 1.9 μL of pre-amplification primer pool, 0.13 μL of AmpliTaq Gold, 0.75 μL of MgCl2, 1.25 μL of 10x PCR Buffer Gold, 1.0 μL of dNTPs and 6.22 μL of ddH2O.

The quantification of targeted miRNAs was performed using TaqMan MicroRNA Assay (Applied Biosystems™ Foster City, CA) on Agilent (Stratagene, La Jolla, CA) MX3005P Multiplex QPCR Real-time Thermal Cycler. For the purpose of quantification of targeted miRNAs,
a mastermix was made with 5 μL of TM Universal mastermix, 0.5 μL of 20x TM Micro RNA Array assay for a particular miRNA and 4.30 μL of ddH2O. The total mastermix volume was 9.80 μL. The qPCR reaction was performed on all miRNAs individually. For each miRNA the appropriate 20x TM Micro RNA Array assay was used. The dye used for miRNA comparative quantitation was FAM. Within each plate a calibrator well was selected for the purpose of normalization of data. Data was organized for each miRNA and necessary replicates were performed.

**Statistical analysis**

Normalization of expression data was performed using Delta Delta Ct, as suggested by [66], which is calculated according to formula: (original Ct value of a sample-calibrator value of the miRNA)—(calibrator of the miRNA from the sample–calibrator of the normalizing miRNA). The normalizing miRNA used in this study was miR-191-5p [67].

Outliers were determined using the Grubbs test via Xlstat add-on with Microsoft Office Excel program. Since obtained results have normalized Ct values, criteria for the classification of an outlier was used. Hence, all normalized expression data values with a z-score over 1.5, for both tails, were classified as outliers. The 1.5 z-score threshold was chosen because the Ct values above that threshold are too high or too low in order to be considered valid [68]. The data was tested for normal distribution using Shapiro Wilk, Anderson-Darling and Jarque-Bera test. The normal distribution tests were performed in the Past 3 program [69] (https://folk.uio.no/ohammer/past/).

Normally distributed data from qRT-PCR were analysed using Student’s T-test while the not-normally distributed data was analysed using Mann-Whitney U test. Logistic regression analysis was used to describe the dependency of the dependent outcome, the diagnosis in this case, and was performed on each miRNA separately. In addition, a logistic regression was performed on multiple sets of variables (miRNAs) in order to predict the diagnosis (ASD or DD). The logistic regression was calculated with Xlstat add-on within the Microsoft Office Excel program.

A Receiver Operating Characteristic (ROC) curve of the created prediction models was also calculated as it can provide an unbiased assessment of the overall model performance. Therefore, the ROC can be used for evaluating the diagnostic power of miRNAs. In order to further support the results found using the logistic regression a multivariate linear regression of Partial Least Squares-Discriminant analysis (PLS-DA) was calculated. The PLS-DA calculates the multivariate linear combinations from the 14 miRNAs of interest that are best predictors of the class of interest. PLS-DA was also calculated with the Xlstat add-on. For all models, a cross validation was performed by randomly dividing the dataset into a training and validation set. The size of training and validation sets were determined based on the sample size being analysed (approximately 10%). Multiple iterations of the models were performed to ensure randomness within the models. Furthermore, parameters chosen were the default parameters (0.5 prediction threshold) and the sporadic missing data was predicted using the nearest neighbour method approach.

**Results**

Out of 14 analysed miRNAs, 6 were differentially expressed between typically developing children and children with some type of developmental disorder (which includes ASD). These were miR-7-5p, miR-23a-3p, miR-32-5p, miR-140-3p, miR-628-5p and miR-2467-5p. Two miRNAs were up-regulated (miR-7-5p and miR-2467-5p), while 4 were down-regulated (miR-23a-3p, miR-32-5p, miR-140-3p and miR-628-5p) (Table 3). MiRNA with largest difference in
average expression was miR-32-5p, followed by miR-23a-3p. Normalized Ct value data for each individual miRNA within the three cohorts was presented in a Box Plot and Jitter graph (Fig 1). Details on the percentage of obtained Ct values for every cohort and for each individual miRNA can be seen in S1 Table.

Out of 14 miRNAs, analysed in ASD samples, 5 were differentially expressed according to Mann Whitney U test. Four miRNAs were down-regulated while one was up-regulated (Table 3). Down-regulated miRNAs within ASD group were miR-23a-3p, miR-32-5p, miR-628-5p and miR-140-3p, while significantly up-regulated was miR-7-5p. MiRNA with the largest difference in average expression was miR-32-5p, followed by miR-23a-3p. Differentially expressed miRNAs within non-ASD group, when compared to the control group, were miR-23a-3p, miR-32-5p, miR-628-5p and miR-2467-5p. MiR-2467-5p was upregulated while the other 3 miRNAs were all down-regulated (Table 3).

Logistic regression performed on individual miRNAs between TD and children with ASD, as a subgroup of DD, has shown that the best performing miRNAs in differentiating between these groups were miR-32-5p (-2Log(Likelihood): 7.363; p-value: 0.007) and miR-23a-3p (-2Log(Likelihood): 5.406; p-value: 0.020). Following these two miRNAs, the best performing were miR-7-5p, miR-218-5p, miR-27a-3p and miR-628-5p, although their GoF statistics were not significant. When the values of ROC AUC were taken into consideration the best performing miRNAs were miR-23-3p, miR-32-5p and miR-7-5p.

Logistic regression was also performed on individual miRNAs between typically developing children and children with some type of developmental disorder (this cohort included ASD and non-ASD DD groups) and the best performing individual miRNA in classifying between these groups were miR-32-5p (-2Log (Likelihood): 11.208; p-value: 0.001) followed by miR-23a-3p (-2Log(Likelihood): 9.507; p-value: 0.002). MiR-628-5p, miR-7-5p and miR-27a-3p have also shown a very good performance in classifying between TD and DD children. Out of the latter 3 miRNAs, only miR-628-5p had significant -2Log(Likelihood) statistic (-2Log

Table 3. Differentially expressed miRNAs within the analysed cohorts and their directional expression changes relative to the control group.

| Cohorts     | Expression pattern (p-value) |
|-------------|------------------------------|
| DD          |                              |
| miR-7-5p    | Up-regulated (0.0361)        |
| miR-23a-3p  | Down-regulated (0.0001)      |
| miR-32-5p   | Down-regulated (0.0001)      |
| miR-140-3p  | Down-regulated (0.0067)      |
| miR-628-5p  | Down-regulated (0.0001)      |
| miR-2467-5p | Up-regulated (0.0499)        |
| ASD         |                              |
| miR-7-5p    | Up-regulated (0.0172)        |
| miR-23a-3p  | Down-regulated (0.0001)      |
| miR-32-5p   | Down-regulated (0.0001)      |
| miR-140-3p  | Down-regulated (0.0053)      |
| miR-628-5p  | Down-regulated (0.0005)      |
| Non-ASD DD  |                              |
| miR-23a-3p  | Down-regulated (0.0033)      |
| miR-32-5p   | Down-regulated (0.0102)      |
| miR-628-5p  | Down-regulated (0.0135)      |
| miR-2467-5p | Up-regulated (0.0057)        |

https://doi.org/10.1371/journal.pone.0232351.t003
When the values of ROC AUC were taken into consideration, miR-32-5p and miR-23a-3p again had the best performance. MiR-628-5p also had a relatively high ROC AUC (0.696).

In the logistic regression on individual miRNAs between non-ASD DD group and typically developing children only one, miR-32-5p, had significant -2Log(Likelihood) statistic of 9.301 with a p-value of 0.002. MiRNAs close to having a statistically significant GoF statistics were miR-23a-3p (-2Log(Likelihood): 3.127; p-value: 0.067) and miR-3529-3p (-2Log(Likelihood): 2.915; p-value: 0.088). For further details please refer to S8–S11 Tables.

PLS-DA performed on TD children and children with ASD had shown that the most contributing miRNAs in creating the PLS-DA were miR-23a-3p, miR-32-5p, miR-7-5p, miR-27a-3p, miR-628-5p and miR-140-3p, in order. The sensitivity and specificity for this PLS-DA model were 64% and 88.57% respectively. The total accuracy was 78.33%. The AUC for the ROC of the PLS-DA model was 0.920. For the PLS-DA performed on TD and DD cohorts, miRNAs with the most significant contribution to PLS-DA model were (from most to least significant): miR-23a-3p, miR-7-5p, miR-32-5p, miR-27a-3p, miR-628-5p, miR-140-3p and miR-2467-5p. The overall prediction model for the PLS-DA had a 36% specificity, 86.27% sensitivity and a total accuracy of 69.74%. For the calculated ROC Curve the AUC was 0.793. MiRNAs with the highest VIP scores were miR-23a-3p, miR-7-5p and miR-32-5p. The PLS-DA on non-ASD DD group and typically developing children had shown that the most contributing miRNAs in creating this PLS-DA prediction model were miR-32-5p, miR-23a-3p, miR-628-5p, miR-7-5p. This PLS-DA model had 88% specificity and 64.29% specificity. The total accuracy and ROC AUC were 79.49% and 0.749, respectively (S6 and S7 Tables).

Fig 1. Box and jitter graph of the normalized Ct values for each miRNA within the three analysed cohorts (TD, ASD and non-ASD DD).
Overfitting was suspected on the logistic regression model of 14 miRNAs which predicted ASD children from TD. That model had maximum specificity and sensitivity for the training set and 66.67% specificity and 100% sensitivity for the validation set. Hence, a more reliable model was created which included 5 miRNAs (best performing in the previously mentioned model) (miR-7-5p, miR-23a-3p, miR-27a-3p, miR-140-3p and miR-2467-5p). The -2Log(Likelihood) value of the model was 40.237 with a p-value of <0.0001. Specificity was 90.00%, sensitivity was 90.32% (Table 4) and the ROC AUC of the model was 0.952. The validation set had an accuracy of 90%.

The logistic regression on the full set of variables performed on typically developing children and children with any type of developmental disorder had a maximum specificity and sensitivity for the training set and 50% specificity and 100% sensitivity for the validation set. Since overfitting was suspected, a model with 7 miRNAs (best performing in the previously mentioned model) (miR-7-5p, miR-23a-3p, miR-27a-3p, miR-32-5p, miR-140-3p, miR-628-5p and miR-2467-5p) was created. The -2Log(Likelihood) for this model was 62.805 with a p-value of <0.0001. The specificity and sensitivity values were 86.36% and 93.18%, respectively (Table 4). The ROC AUC of the model was 0.983. The validation set had an accuracy of 90%. As the logistic regression model on non-ASD DD and TD children also had maximum accuracy, overfitting had to be taken into consideration. Hence, the best performing model on reduced number of miRNAs was based on 5 miRNAs (best performing in the previously mentioned model) (miR-7-5p, miR-23a-3p, miR-32-5p, miR-140-3p, miR-3529-3p). The -2Log(Likelihood) value of the model was 30.013 with a p-value of <0.0001. The specificity and sensitivity values were 92.00% and 75.00% (Table 4) and the ROC AUC of the model was 0.940. The validation set was too small (5 samples) for meaningful conclusions. However, within randomly chosen 5 validation samples 100% accuracy in their classification was observed. Details on the mentioned models can be seen in Fig 2. Furthermore, we have performed a power analysis (where the number of final sample sizes for each miRNA or test can be seen) on all models and individual miRNAs which have shown statistically significant ability in differentiating between cohorts (S2–S5 Tables).

**Discussion**

We have analysed expression of 14 miRNAs in saliva samples of children with DD including ASD and TD. Six miRNAs were found to be differentially expressed in children with DD. Furthermore, when samples of children with ASD were analysed, 5 miRNAs were found to be differentially expressed. All 5 miRNAs from ASD analysis were found within the group of 6 miRNAs differentially expressed in children with DD. Only miR-2467-5p was not differentially expressed among children with ASD. We have found that this particular miRNA had significant difference in abundance in ASD when compared to other DD samples. Out of differentially expressed miRNAs among children with ASD, with the exception of miR-140-3p and miR-628-5p, all had concordant expression patterns to a previously reported study [53].

| Model             | Sensitivity (95% CI)       | Specificity (95% CI)     | Accuracy (95% CI)  |
|-------------------|---------------------------|--------------------------|--------------------|
| TD-DD             | 86.36% (65.09%–97.09%)    | 93.18% (81.34%–98.57%)  | 90.91% (81.26%–96.59%) |
| TD-ASD            | 90.32% (63.66%–96.95%)    | 90% (77.93%–99.18%)     | 90.2% (78.59%–96.74%) |
| TD—non-ASD DD     | 75% (66.27%–95.81%)       | 92% (57.19%–98.22%)     | 85.37% (70.83%–94.43%) |

*CI—Confidence Interval.
In our study miR-140-3p and miR-628-5p were down-regulated, while they were up-regulated in the mentioned study.

Using the most optimal logistic regression model, we were able to distinguish between ASD and TD children. We have found 5 miRNAs as potential biomarkers. Out of these 5 miRNAs, 3 were differentially expressed within the ASD cohort. All 5 miRNAs have shown good chi-square statistics within the logistic regression model which utilized all 14 miRNAs analysed in this study. The accuracy of 5-miRNA logistic regression model training set was 90.20%, while the validation set had a 90% accuracy. The logistic regression performed only on differentially expressed miRNAs between ASD and TD has shown poorer results than the previously discussed model. Moreover, the best logistic regression model which attempted to distinguish between DD and TD children included 7 miRNAs as variables (miRNAs). Six of these were differentially expressed among children with DD while one, which was not differentially expressed (miR-27-3p), has shown a relatively large VIP value within the PLS-DA. This model had a total accuracy of 90.91% in the training set and 90% accuracy within the validation set. The best performing logistic regression model, attempted to differentiate between non-ASD DD and TD cohorts, included 5 variables. Two of the five miRNAs were differentially expressed, while 3 have performed very well in the model which included the complete set of 14 miRNAs. In this study cross validation was used for validating the trained models. In order to obtain more reliable validation results an independent sample cohort for validation would be suitable.

![Fig 2. Comparison of the 4 logistic regression models.](https://doi.org/10.1371/journal.pone.0232351.g002)
The three main prediction models (distinguishing children with ASD, any type of DD or non-ASD developmental disorder from TD) have all shown results with significant GoF statistics and satisfactory accuracy. The model used to differentiate between children with DD and TD had the best performance followed by the model on ASD and TD children. Finally, the model which attempted to differentiate between non-ASD DD and TD children had the poorest performance out of the 3 models. The results obtained from the discussed logistic regressions models were fully supported by the PLS-DA performed on the same groups.

In this study we have found that, individually, the best miRNAs for differentiating between children with ASD or even DD from TD were miR-23-3p and miR-32-5p. The same was true when differentiating non-ASD cohort from TD. It has been found that miR-23a-3p functions cooperatively with miR-27a-3p to regulate cell proliferation and differentiation [70]. Furthermore, miR-23a-3p and miR-27a-3p were also dysregulated in a number of human diseases and disorders, including ASD [49, 53, 71]. Levels of miR-23a-3p also fluctuated in response to CNS injuries such as cerebral ischemia [72] or temporal epilepsy [73], both of which are associated with ASD [74]. MiR-23a-3p was also found to be dysregulated in 3 other studies [42, 45, 49]. MiR-32-5p is believed to be involved in certain processes which promote cell proliferation, migration and suppresses apoptosis in breast cancer while inhibiting proliferation and invasion in gastric cancer cell lines [75, 76].

Studies on biomarkers, as potential diagnostic tools for ASD, have also developed successful prediction models. There have been numerous studies on differentially expressed miRNAs within ASD children including analysis of their suitability as biomarkers [51]. MiR-23a-3p analysed by Hicks et al., 2016 [53], Sarachana et al., 2010 [55] has been shown to be significantly down-regulated. Moreover, when it comes to individual performance of miRNAs, differentially expressed miRNAs in this study had a lower prediction power than in Hicks et al., 2016 [53] or Vasu et al., in 2014 [49]. Prediction models utilizing multiple miRNAs or other types of RNAs as biomarkers for ASD have also been studied and overall show better prediction capabilities. One such example is the study which utilized 14 miRNAs and obtained 95.6% specificity, 100% sensitivity and an area under the ROC curve of 0.974 [53]. In this study, the best individually performing miRNAs were miR-335-3p and miR-30-5p, whereas in our study the best performing miRNAs were miR-23a-3p and miR-32-5p.

In addition, another study [58] used a combination of RNA molecules (1 snoRNA, 8 piRNAs, 4 precursor miRNAs, 7 mature miRNAs and 12 microbial taxa) and reported 78.3% specificity, 79.9% sensitivity and an area under the ROC curve of 0.868. When analysing miRNAs in ASD individuals relatively small percentage of differentially expressed miRNAs overlap between studies. A total of 3 miRNAs showed consistent dysregulation in 3 or more studies [77]. These differences in obtained differentially expressed miRNAs, also applicable to our study, can be explained by the effect of different factors such as age, ethnicity, ASD heterogeneity, different RNA collection devices, RNA quantification and analysis and miRNA role in development. It has been shown that the overall ASD prevalence is higher in males then in females, [78, 79] as was observed in our study. One potential explanation [80] is the female genome resistance and the fact that more severe symptoms are usually required in order for females to be detected [78–81]. As such biases are present across biomarker ASD studies [43, 58], more research would have to be performed in order to determine the effect gender has, if at all, on miRNA expression. The referenced study [53] involved children 5 to 14 years of age. In our study, on the other hand, we involved children (Table 2) 3 to 8 years of age in an attempt to test children as early as possible or as close as possible to ASD diagnosis in order to evaluate the combination of performed tests (clinical and biomarker) and their accuracy in diagnosing ASD. Furthermore, a recent review reported no differences in prevalence across geographic regions or variability based on ethnicity or socioeconomic factors; however, they did add that the lack of
Comprehensive datasets from low-income countries impacts the ability to detect these effects [16]. Therefore, testing miRNAs as biomarkers of ASD in different ethnic groups including those from LMIC’s is absolutely needed. We have found correlation with compared studies as well; however, further model improvement has to be performed on much larger population. In addition, Hicks’ study targeted children with “high functioning” ASD (average ADOS-II score = 10.6 ± 4.1), whereas our study included ASD and DD children classified by CARS-II as Mild-to-Moderate and Severe ASD Symptoms category for ASD and Minimal-to-No Symptoms of ASD CARS-II category for non-ASD DD children. Because salivary miRNA expression is associated with levels of ASD symptoms, it is likely that this also contributes to observed differences in miRNA expression. In order to validate used scale (CARS II) we have randomly selected 26/55 (47%) children for clinical evaluation by child psychiatrist. This validation showed 100% concordance between CARS II and child psychiatrists’ evaluation and confirmed the reliability of the used scale. However, the fact that we performed clinical evaluation on approximately 50% of children may represent a limiting factor on such a validation. In our study we used collection devices (Samplifybio saliva collection kit) different from the referred study [53]. The RNA preservation liquid between the two devices may have, additionally, contributed to miRNA expression differences. Our method of choice was RT-PCR as a relatively cheap and available method in most medical labs in LMIC. Therefore, we expected differences in expression and detection obtained by RT-PCR when compared to a more robust sequencing method used by Hicks et al. 2016. Nonetheless, models utilizing salivary miRNA and detection with RT-PCR can be used to differentiate children with ASD from typically developing or non-ASD DD children [30]. However, in order to improve their specificity and make them applicable in clinical setting, the proposed models have to be tested on a larger population and potentially, as suggested by Hicks et al. 2018, by employing a multi-“omic” approach using additional RNA families.

Furthermore, as miRNA expression is a dynamic process which changes throughout development we have to consider its effect on miRNA expression differentiation [43] However, it has been shown that miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex [43]. Although there is a chance that some of the found differences are affected by the miRNA involvement in neural development, majority of our findings are on children of average age of 5 and same ethnicity. Looking at the younger children such as infants and toddlers may shed more light in the future on the potential differences in miRNA expression due to developmental processes better.

Finally, in an earlier in silico study [82] target mRNAs of the same 14 miRNAs were analysed. Genes reported to be targeted by all 14 miRNAs and have more than 7 predicted target sites were: MAPK10, KCNMA1 and DST. The number of predicted sites was used as an indirect measure of how correlated an mRNA was with the miRNA in question. In the same study, genes reported to be targeted by 13 miRNAs and have more than 7 predicted target sites were reported. Those genes were ZBTB20, GAS7, NTRK2 and SCN2A. It is thought that most of these genes are related to neural processes and are directly or indirectly related to ASD. According to Hicks et al., 2016 [49] the notable ASD-associated mRNA targets of these 14 miRNAs are Fragile X Mental Retardation (FMR1) and Forkhead Box Protein P2 (FOXP2). Those mRNAs predicted to have a function most relevant to ASD were mapped to the Neuron Projection and Axon Projection subnodes.

**Conclusion**

This study has shown that miRNAs can be considered as biomarkers for ASD diagnosis and could be used to identify children with ASD at a very early stage of life. We performed a
transdisciplinary cooperation in order to define the most optimal and accurate approach in identifying children with developmental disorders, including ASD, in low to mid income countries such as Bosnia and Herzegovina. We have done this by utilizing a combination of molecular analysis, based on miRNAs as biomarkers, and screening methods such as EDUS-DBS, CARS II and clinical analysis. Our molecular analysis was based on a panel of 14 miRNAs previously shown as good biomarkers for ASD. We have found that even subsets of this panel of miRNAs have the potential to be used as diagnostic biomarkers for ASD and/or DD. Out of 14 miRNAs analysed in this study, miR-32-5p, miR-23a-3p and miR-7-5p, have been found as good candidates for biomarkers in differentiating children with ASD from typically developing children. The best miRNAs for differentiating between children with any type of developmental disorder and typically developing children were miR-23a-3p, miR-32-5p and miR-628-5p. As previously suggested, a good step towards implementing miRNAs as ASD or DD biomarkers would be large scale validation study with multi-"omics" approach along with currently employed screening tests. This would lead to an optimized biomarker diagnostic tool that complements current screening tests.

Supporting information

S1 Table. Percentage of obtained Ct values for every cohort and for each individual miRNA. (DOCX)

S2 Table. Shown is the detailed logistic regression performance of individual miRNAs between TD and DD cohorts. (DOCX)

S3 Table. Shown is the detailed logistic regression performance of individual miRNAs between TD and ASD cohorts. (DOCX)

S4 Table. Shown is the detailed logistic regression performance of individual miRNAs between TD and non-ASD DD cohorts. (DOCX)

S5 Table. Shown is the detailed logistic regression performance of individual miRNAs between ASD and non-ASD DD cohorts. (DOCX)

S6 Table. Details on performance of the PLS-DA prediction models on the analysed cohorts. (DOCX)

S7 Table. MiRNAs with Variable Importance in Projection (VIP) value over 1.0 for each cohort within the PLS-DA. (DOCX)

S8 Table. Power analysis (where the number of final sample sizes for each miRNA or test can be seen) on logistic regression which have shown statistically significant ability in differentiating between cohorts. (DOCX)

S9 Table. Power analysis on Mann-Whitney U test on TD-DD cohorts. (DOCX)
S10 Table. Power analysis on Mann-Whitney U test on TD–ASD cohorts.

(DOCX)

S11 Table. Power analysis on Mann-Whitney U test on TD–non-ASD DD cohorts.

(DOCX)

S1 File.

(XLSX)

Author Contributions

Conceptualization: Lejla Smajlovic-Skenderagic, Nirvana Pistoljevic, Eldin Dzanko, Aida Hajdarpasic.

Data curation: Emir Sehovic, Lemana Spahic, Nirvana Pistoljevic, Eldin Dzanko, Aida Hajdarpasic.

Formal analysis: Emir Sehovic, Lemana Spahic, Lejla Smajlovic-Skenderagic, Eldin Dzanko, Aida Hajdarpasic.

Funding acquisition: Nirvana Pistoljevic, Aida Hajdarpasic.

Investigation: Emir Sehovic, Lemana Spahic, Aida Hajdarpasic.

Methodology: Emir Sehovic, Lemana Spahic, Lejla Smajlovic-Skenderagic, Eldin Dzanko, Aida Hajdarpasic.

Project administration: Nirvana Pistoljevic, Aida Hajdarpasic.

Resources: Aida Hajdarpasic.

Supervision: Lejla Smajlovic-Skenderagic, Aida Hajdarpasic.

Validation: Aida Hajdarpasic.

Visualization: Emir Sehovic.

Writing – original draft: Emir Sehovic, Lemana Spahic, Nirvana Pistoljevic, Eldin Dzanko, Aida Hajdarpasic.

Writing – review & editing: Lejla Smajlovic-Skenderagic, Nirvana Pistoljevic, Aida Hajdarpasic.

References

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed. Washington; 2013.
2. Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. Journal of medical genetics. 2009; 46 (1): 1–8. https://doi.org/10.1136/jmg.2008.060871 PMID: 18728070
3. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Current opinion in genetics & development. 2012; 22(3): 229–237.
4. Toriello HV. Approach to the genetic evaluation of the child with autism. Pediatric Clinics. 2012; 59(1): 113–128. https://doi.org/10.1016/j.pcl.2011.10.014 PMID: 22284797
5. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torio G, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Archives of general psychiatry. 2011; 68(11): 1095–1102. https://doi.org/10.1001/archgenpsychiatry.2011.76 PMID: 21727249
6. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse MeCP2-null mutation causes neurological symptoms that mimic Rett syndrome. Nature genetics. 2001; 27(3): 322. https://doi.org/10.1038/85899 PMID: 11242117
7. Kubota T, Das S, Christian SL, Baylin SB, Herman JG, Ledbetter DH. Methylation-specific PCR simplifies imprinting analysis. Nature genetics. 1997; 16(1): 16. https://doi.org/10.1038/ng0597-15 PMID: 9140389
8. Kubota T, Nonoyama S, Tonoki H, Masuno M, Imaizumi K, Kojima M, et al. A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR. Human genetics. 1999; 104(1): 49–55.
9. Xue F, Tian XC, Du F, Kubota C, Taneja M, Dinneyes A, et al. Aberrant patterns of X chromosome inactivation in bovine clones. Nature genetics. 2002; 31(2): 216. https://doi.org/10.1038/ng900 PMID: 12032569
10. Nolen LD, Gao S, Han Z, Mann MR, Chung YG, Otte AP, et al. X chromosome reactivation and regulation in cloned embryos. Developmental biology. 2005; 279(2): 525–540 https://doi.org/10.1016/j.ydbio.2005.01.016 PMID: 15733677
11. Kubota T, Wakui K, Nakamura T, Ohashi H, Watanabe Y, Yoshino M, et al. The proportion of cells with functional X disomy is associated with the severity of mental retardation in mosaic ring X Turner syndrome females. Cytogenetic and genome research. 2002; 99(1–4): 276–284. https://doi.org/10.1159/000071604 PMID: 12900575
12. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature genetics. 1999; 23(2): 185. https://doi.org/10.1038/ng13810 PMID: 10508514
13. Landrigan PJ. What causes autism? Exploring the environmental contribution. Current opinion in pediatrics. 2010; 22(2):219–225.
14. Jung CR, Lin YT, Hwang BF. Air pollution and newly diagnosed autism spectrum disorders: a population-based cohort study in Taiwan. PloS One. 2013; 8(9):e75510. https://doi.org/10.1371/journal.pone.0075510 PMID: 24086549
15. Hulusic V, Pistoljevic N. Read, play and learn: an interactive e-book for children with autism. In: International Conference on Games and Learning Alliance. 2015; Dec 9: 255–265. Springer, Cham.
16. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcini C, et al. Global prevalence of autism and other pervasive developmental disorders. Autism research. 2012; 5(3): 160–179. https://doi.org/10.1002/aur.239 PMID: 22495912
17. Kim YS, Leventhal BL, Koh YJ, Fombonne E, Lim EC, et al. Prevalence of autism spectrum disorders in a total population sample. American Journal of Psychiatry. 2011; 168(9): 904–912. https://doi.org/10.1176/appi.ajp.2011.10101532 PMID: 21558103
18. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveillance Summaries. 2018; 67(6): 1.
19. Bachmann CJ, Gerste B, Hoffmann F. Diagnoses of autism spectrum disorders in Germany: time trends in administrative prevalence and diagnostic stability. Autism. 2018; 2(3): 283–290.
20. Onaolapo AY, Onaolapo OJ. Global data on Autism spectrum disorders prevalence: A review of facts, fallacies and limitations. Universal Journal of Clinical Medicine. 2017; 5(2): 14–23.
21. Xu G, Stratthamm L, Liu B, Bao W. Prevalence of autism spectrum disorder among US children and adolescents, 2014–2016. Jama. 2018; 319(1): 81–82. https://doi.org/10.1001/jama.2017.17812 PMID: 29297068
22. Surén P, Bakken LJ, Lie KK, Schjelberg S, Aase H, Reichborn-Kjennerud T, et al. Differences across counties in the registered prevalence of autism, ADHD, epilepsy and cerebral palsy in Norway. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2013; 133(18): 1929–1934.
23. Duby JC, Lipkin PH, Macias MM, Wegner LM, Duncan P, Hagan JF, et al. Identifying infants and young children with developmental disabilities in the medical home: An algorithm for developmental surveillance and screening. Pediatrics. 2006; 118(1): 405–420. https://doi.org/10.1542/peds.2006-1231 PMID: 16818591
24. Siu AL, Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, Ebell M, et al. Screening for autism spectrum disorder in young children: US Preventive Services Task Force recommendation statement. Jama. 2016; 315(7): 691–696. https://doi.org/10.1001/jama.2016.0018 PMID: 26881372
25. World Bank. Bosnia and Herzegovina—Country partnership framework for the period FY2016-20. Washington, D.C. World Bank Group. 2015. http://documents.worldbank.org/curated/en/752481468194999174/Bosnia-and-Herzegovina-Country-partnership-framework-for-the-period-FY2016-20
26. Elder JH, Kreider CM, Brasheer SN, Ansell M. Clinical impact of early diagnosis of autism on the prognosis and parent–child relationships. Psychology research and behaviour management. 2017.
27. Brown TT, Jernigan TL. Brain development during the preschool years. Neuropsychology review. 2012; 22(4): 313–333. https://doi.org/10.1007/s11065-012-9214-1 PMID: 23007644

28. Tierney AL, Nelson III CA. Brain development and the role of experience in the early years. Zero to three. 2009; 30(2): 9. PMID: 23894221

29. Collins PY, Pringle B, Alexander C, Darmstadt GL, Heymann J, Huebner G, et al. Global services and support for children with developmental delays and disabilities: Bridging research and policy gaps. PLoS Medicine. 2017; 14(9): e1002393. https://doi.org/10.1371/journal.pmed.1002393 PMID: 28922419

30. Hicks SD, Carpenter RL, Wagner KE, Pauley R, Barros M, Tierney-Aves C, et al. Saliva MicroRNA Differentiates Children with Autism From Peers With Typical and Atypical Development. Journal of the American Academy of Child & Adolescent Psychiatry. 2019.

31. Gallo A., Tandon M., Alevizos I., & Illei G. G. (2012). The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PloS one, 7(3).

32. Abraham J. E., Maranian M. J., Spiteri I., Russell R., Ingle S., Luccarini C., et al. (2012). Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping. BMC medical genomics, 5(1), 19.

33. Zubakov D., Hanekamp E., Kokshoorn M., van IJcken W., & Kayser M. (2008). Stable RNA markers for identification of blood and saliva stains revealed from whole genome expression analysis of time-wise degraded samples. International journal of legal medicine, 122(2), 135–142. https://doi.org/10.1007/s00414-007-0182-6 PMID: 17579879

34. Bahlo M., Stankovich J., Danoy P., Hickey P. F., Taylor B. V., Browning S. R., et al. (2010). Saliva-derived DNA performs well in large-scale, high-density single-nucleotide polymorphism microarray studies. Cancer Epidemiology and Prevention Biomarkers, 19(3), 794–798.

35. Wu YE, Parikh NN, Belgard TG, Geschwind DH. Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder. Nature neuroscience. 2016; 19(11): 1463. https://doi.org/10.1038/nn.4373 PMID: 27571009

36. Ambros V. The functions of animal microRNAs. Nature. 2004; 431(7006): 350. https://doi.org/10.1038/ nature02871 PMID: 15372042

37. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. PloS One. 2012; 7(7): e41561. https://doi.org/10.1371/journal.pone.0041561 PMID: 22859996

38. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biology. 2004; 2(11): e363. https://doi.org/10.1371/journal.pbio.0020363 PMID: 15502875

39. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1): 15–20. https://doi.org/10.1016/j.cell.2004.12.035 PMID: 15652477

40. Schratt G. MicroRNAs at the synapse. Nature Reviews Neuroscience. 2009; 10(12): 842 https://doi.org/10.1038/nrn2763 PMID: 19888283

41. Kos A, Loohuis NO, Meinhardt J, van Bokhoven H, Kaplan BB, Martens GJ, et al. MicroRNA-181 promotes synaptogenesis and attenuates axonal outgrowth in cortical neurons. Cellular and molecular life sciences. 2016; 73(18): 3555–3567. https://doi.org/10.1007/s00018-016-2179-0 PMID: 27017280

42. Wang W, Kwon EJ, Tsai LH. MicroRNAs in learning, memory, and neurological diseases. Learning & Memory. 2012; 19(9): 359–368.

43. Tonelli DD, Pulvers JN, Haffner C, Murchison EP, Hannon GJ, Huttner WB. MiRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex. Development. 2008; 135(23): 3911–3921. https://doi.org/10.1242/dev.025080 PMID: 18997113

44. Im HI, Kenny PJ. MicroRNAs in neuronal function and dysfunction. Trends in neurosciences. 2012; 35(5): 325–334. https://doi.org/10.1016/j.tins.2012.01.004 PMID: 22436491

45. Karam R, Wilkinson MA. Conserved microRNA/NMD regulatory circuit controls gene expression. RNA biology. 2012; 9(1): 22–26. https://doi.org/10.4161/rna.9.1.18010 PMID: 22258150

46. Abu-Eineel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics. 2008; 9(3): 153–161. https://doi.org/10.1007/s10048-008-0133-5 PMID: 18563458

47. Mor M, Nardone S, Sams DS, Elliott E. Hypomethylation of miR-142 promoter and upregulation of microRNAs that target the oxytocin receptor gene in the autism prefrontal cortex. Molecular autism. 2015; 6(1): 46.
48. Ander BP, Barger N, Stamova B, Sharp FR, Schumann CM. Atypical miRNA expression in temporal cortex associated with dysregulation of immune, cell cycle, and other pathways in autism spectrum disorders. Mol Autism. 2015; 6: 37. https://doi.org/10.1186/s13229-015-0029-9 PMID: 26146533

49. Vasu MM, Anitha A, Thanseem I, Suzuki K, Yamada K, Takahashi T, et al. Serum microRNA profiles in children with autism. Molecular autism. 2014; 5(1): 40.

50. Huang F, Long Z, Chen Z, Li J, Hu Z, Qiu R, et al. Investigation of gene regulatory networks associated with autism spectrum disorder based on MiRNA expression in China. PLoS One. 2015; 10(6): e0129052. https://doi.org/10.1371/journal.pone.0129052 PMID: 26061495

51. Vaccaro T, Sorrentino J, Salvador S, Veit T, Souza D, de Almeida R. Alterations in the MicroRNA of the Blood of Autism Spectrum Disorder Patients: Effects on Epigenetic Regulation and Potential Biomarkers. Behavioral Sciences. 2018; 8(8): 75.

52. Popov NT, Madjirova NP, Minkov IN, Vachev TI. MicroRNA HSA-486-3P gene expression profiling in the whole blood of patients with autism. Biotechnol Biotechnol Equip. 2012; 26(6): 3385–8.

53. Hicks F.D., Ignacio C., Gentile K., & Middleton F. A. (2016). Salivary miRNA profiles identify children with autism spectrum disorder, correlate with adaptive behavior, and implicate ASD candidate genes involved in neurodevelopment. BMC pediatrics, 16(1), 52.

54. Nguyen LS, Lepleux M, Makhlof M, Martin C, Fregeac J, Siquier-Pernet K, et al. Profiling olfactory stem cells from living patients identifies miRNAs relevant for autism pathophysiology. Mol Autism. 2016; 7(1): 1.

55. Sarachana T, Zhou R, Chen G, Manji HK, Hu VW. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome medicine. 2010; 2(4): 23. https://doi.org/10.1186/gm144 PMID: 20374639

56. Talebizadeh Z, Butler MG, Theodorou MF. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Research. 2008; 1(4): 240–250. https://doi.org/10.1002/aur.33 PMID: 19360674

57. Seno MMG, Hu P, Gwadry FG, Pinto D, Marshall CR, Casallo G, et al. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res. 2011; 1380: 85–97. https://doi.org/10.1016/j.brainres.2010.09.046 PMID: 20868653

58. Hicks SD, Rajan AT, Wagner KE, Barns S, Carpenter RL, Middleton FA. Validation of a salivary RNA test for childhood autism spectrum disorder. Frontiers in Genetics. 2018; Nov 9: 9:534. https://doi.org/10.3389/fgene.2018.00534 PMID: 30473075

59. Greer R. D., Keohane D. D., & Healy O. (2002). Quality and comprehensive applications of behavior analysis to schooling. The Behavior Analyst Today, 3, 120–132.

60. Greer R. D., & Ross D. E. (2008). Verbal behavior analysis: Inducing and expanding complex communication in children with severe language delays. Boston, MA: Allyn & Bacon.

61. Lamm N., & Greer R. D. (1991). A systematic replication and a comparative analysis of CABAS. Journal of Applied Behavior Analysis, 24, 107–117. https://doi.org/10.1901/jaba.1991.24-107 PMID: 1829071

62. Selinske J. E., Greer R. D., & Lodhi S. (1991). A functional analysis of the comprehensive application of behavior analysis to schooling. Journal of Applied Behavior Analysis, 24, 107–117. https://doi.org/10.1901/jaba.1991.24-107 PMID: 1829071

63. Greer R. D. (1997). The comprehensive application of behavior analysis to schooling (CABAS®). Behavior and Social Issues, 7(1), 59–63.

64. Pistoljevic N, Zubcevic S, Dzanko E. Developmental behavioral screening and monitoring tool; Early childhood developmental assessment from first month through 6 years-old. Sarajevo: UNICEF. 2016.

65. Schopler E, Van Bourgondien ME, Wellman GJ, Love SR. Childhood autism rating scale—Second edition (CARS2): Manual. Los Angeles: Western Psychological Services. 2010

66. Rai SN, Ray HE, Yuan X, Pan J, Hamid T, Prabhoo SD. Statistical analysis of repeated microRNA high-throughput data with application to human heart failure: A review of methodology. Open access medical statistics. 2012; 2012(2): 21. https://doi.org/10.2147/OAMS.S27907 PMID: 24738042

67. Schwarzenbach H, da Silva AM, Calin G, Pantel K. Data normalization strategies for microRNA quantification. Clinical chemistry. 2015; 61(11): 1333–1342. https://doi.org/10.1373/clinchem.2015.239459 PMID: 26408530

68. Cheadle C., Vawter M. P., Freed W. J., & Becker K. G. (2003). Analysis of microarray data using Z score transformation. The Journal of molecular diagnostics, 5(2), 73–81. https://doi.org/10.1016/S1525-1578(10)60452-2 PMID: 12707371

69. Hammer Ø, Harper D, Ryan P. PAST: Paleontological statistics software package for education and data analysis. Palaeoentronica. 2001; 4(1): 9.
70. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a–27a–24–2 cluster and its implication in human diseases. Molecular cancer. 2010; 9(1): 232.

71. Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K, et al. MiR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MXI1. International journal of oncology. 2013; 42(2): 757–766. https://doi.org/10.3892/ijo.2012.1742 PMID: 23254855

72. Siegel C, Li J, Liu F, Benashski SE, McCullough LD. MiR-23a regulation of X-linked inhibitor of apoptosis (XIAP) contributes to sex differences in the response to cerebral ischemia. Proceedings of the National Academy of Sciences. 2011; 108(28): 1162–1167.

73. Song YJ, Tian XB, Zhang S, Zhang Y X, Li X, Li D, et al. Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b. Brain research. 2011; 1387: 134–140. https://doi.org/10.1016/j.brainres.2011.02.073 PMID: 21376023

74. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proceedings of the National Academy of Sciences. 1997; 94(10): 5395–5400.

75. Jones MH, Furlong RA, Burkin H, Jennifer Chalmers I, Brown GM, Khwaja O, et al. The Drosophila developmental gene fat facets has a human homologue in Xp11. 4 which escapes X-inactivation and has related sequences on Yq11. 2. Human molecular genetics. 1996; 5(11): 1695–1701. https://doi.org/10.1093/hmg/5.11.1695 PMID: 8922996

76. Velayos-Baeza A, Vettori A, Copley RR, Dobson-Stone C, Monaco AP. Analysis of the human VPS13 gene family. Genomics. 2004; 84(3): 536–549. https://doi.org/10.1016/j.ygeno.2004.04.012 PMID: 15498460

77. Hicks S. D., & Middleton F. A. (2016). A comparative review of microRNA expression patterns in autism spectrum disorder. Frontiers in psychiatry, 7, 176. https://doi.org/10.3389/fpsyt.2016.00176 PMID: 27867363

78. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res. 2009; 65:591–598. https://doi.org/10.1203/PDR.0b013e31819e7203 PMID: 19218885

79. Werling DM, Geschwind DH. Sex differences in autism spectrum disorders. Curr Opin Neurol. 2013; 26:146–153. https://doi.org/10.1097/WCO.0b013e32835ee548 PMID: 23406909

80. Masi A, DeMayo MM, Glozier N, Guastella AJ. An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options. Neurosci Bull. 2017; 33(2):183–193. https://doi.org/10.1007/s12264-017-0100-y PMID: 28213805

81. Frazier TW, Georgiades S, Bishop SL, Hardan AY. Behavioral and cognitive characteristics of females and males with autism in the Simons Simplex Collection. J Am Acad Child Adolesc Psychiatry 2014, 53: 329–340.e321–323. https://doi.org/10.1016/j.jaac.2013.12.004 PMID: 24565360

82. Šehović, E., Spahić, L., Kulagić, A., Smajlović-Skenderagić, L. & Hajdaрапavić-Saračević, A. Analysis of miRNA targets in correlation to neurodevelopment and diagnosis of autism spectrum disorder (ASD). CMBEBIH 2019. IFMBE Proceedings, Springer. 2019.